Absci Corporation stocks have been trading up by 10.86 percent following upbeat news on its AI-driven drug discovery progress.
Weekly Update May 25 – May 29, 2026: On Sunday, May 31, 2026 Absci Corporation stock [NASDAQ: ABSI] is trending up by 10.86%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – positive
Absci (ABSI) is a pre-revenue, platform-stage biotech with extreme negative profitability (EBIT margin below -6,000%) and minimal Q1 2026 revenue of $0.2M, down sharply on a multiyear basis. Cash burn is heavy (Q1 operating cash flow -$26.3M; FCF -$26.3M), but the balance sheet is clean: cash and short-term investments of ~$126M, current ratio 6.6, and negligible debt (D/E 0.03). Valuation is rich (P/S ~573x, P/B ~6x), fully dependent on ABS-201 and platform validation.
Technically, ABSI is in a short-term uptrend: the stock climbed from ~$5.16 to ~$6.74 over the last four weekly data points, with higher highs and higher lows, consistent with improving sentiment post-analyst initiations. In 5‑minute action, liquidity has supported clean breakouts above prior resistance near $5.50–5.75. An actionable trading level is $6.00: above that, long entries targeting $7.25–7.50 are favored, while a close back below $5.50 would invalidate the near-term bullish structure.
News flow is strongly supportive: JonesResearch and BTIG both carry Buy ratings with $9–$11 targets, highlighting ABS-201’s “GLP‑1‑like” potential in hair loss and endometriosis and confirming clean early safety. Relative to broader Healthcare and Biotech indices, ABSI screens higher risk but higher upside, with consensus targets implying substantial upside from ~$6–7. I see fair value at $8–9 over 12–18 months, with support at $5.50 and resistance at $7.50, then $9.
Quick Financial Overview
Absci Corporation (ABSI) sits at the intersection of AI and biotech, and that shows up in both the chart and the numbers. On the weekly tape, ABSI pushed from roughly the low-$5 range to the high-$6s, with a recent close near $6.74 after trading as high as about $6.99. That is a sharp multi-day extension off the $5 area and tells you new money is chasing the BTIG and JonesResearch upgrades.
Intraday, the 5‑minute data show a powerful range from just under $6 to above $7, closing near the highs around $6.75. That kind of wide, elevated bar is what you see when a stock re-rates on fresh catalysts and short-term traders pile in. For active traders, prior levels near $5.20–$5.30 now look like key support, while the $7 zone is the first real test of upside follow-through.
Financially, Absci Corporation is still a heavy cash-burn story. Quarterly revenue was only about $0.22M, with gross margin near 100% but operating loss around $30M and free cash flow roughly -$26M. The balance sheet, however, shows cash and short-term investments of about $125.7M, current ratio near 6.6, and very low debt, giving ABSI runway to fund its AI drug creation work and ABS-201 development. Valuation is rich on traditional metrics, with price-to-sales over 500 and negative returns, so this is a pure execution and data-catalyst trade, not a value play.
More Breaking News
- DELL Stock Soars As AI Server Boom Rewrites The Story
- RZLV Stock Climbs As Tata Deal Validates AI Retail Push
- DELL Stock Soars As AI Server Boom Resets Wall Street Expectations
- SoundHound AI Stock Whipsaws As Revenue Soars And Analysts Reset Targets
Conclusion
ABSI is trading like a classic high-beta biotech AI story: small revenue today, large optionality tied to one main asset. The bullish Wall Street tone, led by BTIG’s Buy and $9 target plus JonesResearch’s move to $11, signals that many expect meaningful upside if ABS-201 delivers on hair loss and endometriosis. On the other side, Morgan Stanley’s $4.10 Equal Weight reminds traders that timelines are long, clinical risk is real, and the current valuation already prices in a lot of hope.
From a trading standpoint, the recent surge from just above $5 to the high-$6s puts ABSI in a new range where volatility is likely to stay elevated. Strong cash, minimal debt, and ongoing option grants around $4.92 show Absci Corporation is built to keep funding its AI platform, but the income statement is deeply red, so the story lives and dies on future data. For short-term traders, that means respecting both the upside trend and the downside gap risk if sentiment flips. As millionaire penny stock trader and teacher Tim Sykes, says, “Preparation plus patience leads to big profits.”, and those words are especially relevant when timing entries and exits in a fast-moving name like this.
This remains a textbook high-risk/high-reward biotech AI trade, best handled with clear levels, defined risk, and no denial if the tape turns. As I tell my students, “Your edge in names like Absci Corporation is not predicting the science; it’s managing the volatility with discipline while the market prices that science in.””,”scores”:{“risk-level”:”high”},”trade”:”true
This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.
Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:
- Penny Stocks Trading Guide
- Best Penny Stocks Under $1 to Buy Today
- Top 8 Penny Stocks to Watch on Robinhood
Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:
Leave a reply